We invest in discovery to create products that make life better for people.
Being informed about the facts of cataract surgery & your eyes condition is the first step toward getting the right care.
Our mission is to be a source of inspiration in the field of Biotechnology through sustainable innovation and development.
We manage our technology and produce innovative Biotechnology products following HCP needs and pursuing solutions that maximize value.
We develop innovative solutions that focus on patient and healthcare professionals satisfaction by creating superior state-of-the-art medical products.
Our R&D aim is to enhance and improve the life qualities of the patients around the globe.
VSY Biotechnology GmbH is a biotechnology company with core competencies in the fields of Ophthalmology and Orthopedics.
The company is owned by Evmann Investments Holding BV at 100%. Evmann Investments Holding BV is a Dutch resident Holding company which currently has investments in ophthalmology and orthopedics industries. Its strategy is to make investments especially in areas creating value for a healthier life under its motto of “Invest for Life”.
ARE YOU A HEALTHCARE PROFESSIONAL?
Please note you are entering now content intended only for Healthcare Professionals.
A new Gold Standard trifocal FLACS combined with mini invasive
AcrivaUD Trinova IOL Our Experience
Why do we use Acriva Trinova Trifocal IOL, ESCRS 2018
Newer Designs in Trifocal Lenses Acriva Trinova IOL
Refractive Outcomes after Sinusoidal Trifocal IOL Implantation in Presbyopic Patients
Clinical Outcomes of Sinusoidal Trifocal IOL, Acriva Trinova
Trifocal IOL evolution
Benefits of Sinusoidal Trifocal Technology compared to Blazed Diffractive Trifocal Technology
Tips and Tricks for Succesful Trifocal toric IOL Implantation, Satellite Symposium 2019
Less for more Spectacle independence and decreased photic phenomena with the Acriva Trinova
The Revolutionary SVT Technology of the Acriva Trinova
My First Experience with Trinova IOL, ESCRS 2018
Acriva Trinova Efficiency, predictability and refractive tolerance, ESCRS 2019
Sinusoidal TRIFOCAL IOL with EDOF combination initial outcomes
Refracctive Outcomes afer Sinusoidal Trifocal IOL Implantation in Presbyopic Patients Webinar Presentation
Six-month Clinical outcomes of New trifocal intraocular lenses using the Sinusoidal Pattern with Enhanced Depth of Focus, Satellite Symposium 2019
The Excellent Performances of New Generation Sinusoidal Trifocal IOL, ACRIVA TRINOVA
Initial Experience with Acriva Trinova
Clinical Results of Implantation of the New Sinusoidal Trifocal IOL, ESCRS Vienna 2018-09
Refractive Lensectomy with Acriva, ESCRS Vienna 2011-09
A Novel Approach to Trifocal IOL Technology, Webinar session
Visual Outcomes and Patient Satisfaction with Acriva Trinova Sinusoidal Trifocal IOL, ESCRS 2018
Acriva Trinova “How Trinova platform performs differently from other Trifocals”, ESCRS 2018
The World's First and Only Sinusoidal Trifocal IOL
On top of the sine wave First Outcomes with the AcrivaUD Trinova IOL
Clinical Outcomes of “Reviol toric IOL” in Asian Eyes, ESCRS 2015